DEPEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depen, and when can generic versions of Depen launch?
Depen is a drug marketed by Mylan Speciality Lp and is included in one NDA.
The generic ingredient in DEPEN is penicillamine. There are eighteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the penicillamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depen
A generic version of DEPEN was approved as penicillamine by WATSON LABS INC on June 24th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DEPEN?
- What are the global sales for DEPEN?
- What is Average Wholesale Price for DEPEN?
Summary for DEPEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 105 |
Patent Applications: | 3,597 |
Drug Prices: | Drug price information for DEPEN |
What excipients (inactive ingredients) are in DEPEN? | DEPEN excipients list |
DailyMed Link: | DEPEN at DailyMed |
Pharmacology for DEPEN
Drug Class | Antirheumatic Agent |
US Patents and Regulatory Information for DEPEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Speciality Lp | DEPEN | penicillamine | TABLET;ORAL | 019854-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |